Neoprobe’s Lymphoseek meets all endpoints in Phase 3 study
Neoprobe’s (AMEX:NEOP) Lymphoseek has met all primary and secondary endpoints in the NEO3-09 Phase 3 study, highlighting the superior performance by Lymphoseek, compared with vital blue dye in...
View ArticleInvestigators report Phase 3 Lymphoseek results at ASCO
Independent investigators at the annual meeting of ASCO reported full results from the NEO3-09 study, reaffirming earlier top-line results that showed Neoprobe’s (AMEX:NEOP) Lymphoseek met all primary...
View Article
More Pages to Explore .....